Patent protection in India is governed by the Patents Act, 1970 (as amended in 1999, 2002, and 2005 to comply with TRIPS) and the Patents Rules, 2003, most recently overhauled by the Patents (Amendment) Rules, 2024 (notified 15 March 2024). The nodal authority is the Controller General of Patents, Designs & Trade Marks (CGPDTM) under the DPIIT, Ministry of Commerce and Industry, with four Patent Office branches — Kolkata (head office), Mumbai, Chennai, and Delhi — each having defined territorial jurisdiction.

Patentability :

Under Section 2(1)(j), an “invention” must be a new product or process involving an inventive step and capable of industrial application. Three cumulative tests apply:

• Novelty — not anticipated by any prior publication or use anywhere.
• Inventive step — not obvious to a person skilled in the art; must show technical advance or economic significance.
• Industrial applicability — must have practical, functional utility.

Even if these are satisfied, Sections 3 and 4 exclude several categories: frivolous inventions; inventions contrary to public order or morality; mere discoveries of natural phenomena; Section 3(d) — new forms of known substances lacking enhanced efficacy (the anti-evergreening provision); mere admixtures without synergy; agricultural/horticultural methods; medical/surgical treatment methods; plants and animals (other than micro-organisms); Section 3(k) — mathematical/business methods, computer programs per se, and algorithms; and atomic energy inventions. Software claims can still succeed if they show a genuine “technical effect,” as clarified in Ferid Allani.

Prior Art Search :

Though not statutorily mandatory, a prior art search is essential practical diligence before drafting. It confirms novelty, helps frame distinguishing claims, and anticipates likely examiner objections. Key resources: InPASS (India’s own database), Espacenet (EPO), WIPO Patentscope, USPTO Patent Public Search, and Google Patents/Lens.org for broader and non-patent literature coverage. A sound methodology involves identifying IPC/CPC classification codes, building a keyword matrix, running combined searches across these databases, and preparing a claim chart against the closest prior art. Professional novelty searches typically cost ₹15,000–₹30,000.

Provisional and Complete Specification :

Filed on Form 2 under Section 9:

Provisional specification

Filed when the invention is still developing, to lock in a priority date. It need not contain claims. A complete specification must follow within 12 months (non-extendable), failing which the application is deemed abandoned.

Complete specification

The operative legal document under Section 10, containing title, background, full description (including “best mode”), claims, abstract (≤150 words), drawings, and sequence listings where relevant. Claims should be drafted with a broad independent claim and narrower dependent fallback claims, and should be framed to avoid Section 3 objections (e.g., emphasizing technical effect for software, or including comparative efficacy data for pharmaceutical variants to meet Section 3(d)).

Applicants may also file directly with a complete specification, skipping the provisional stage.

Filing Procedure :

1. Determine applicant category (natural person/startup/small entity/educational institution vs. “large entity” — others) since this determines the fee slab.
2. Obtain a Digital Signature Certificate for e-filing.
3. Prepare Form 1 (application), Form 2 (specification), Form 3 (foreign filing disclosure), Form 5 (inventorship declaration), Form 26 (Power of Attorney, if via agent), and Form 28 (fee concession claim).
4. File via the IPO’s e-filing portal (ipindiaonline.gov.in), upload documents, apply the DSC, and pay fees online.
5. E-filing carries a 10% discount over physical filing.

Publication :

Applications are published in the Official Journal 18 months from priority/filing date (Section 11A), or earlier on request (Form 9, with fee). Publication opens the pre-grant opposition window and enables a later claim to reasonable royalty for the pre-grant period.

Examination :

Examination is not automatic — a Request for Examination (RFE) must be filed. Under the 2024 amendment, this deadline was reduced from 48 to 31 months from priority/filing date for applications filed on or after 15 March 2024 (earlier applications retain 48 months).

Expedited examination (Form 18A) is available to startups, small entities, women applicants, government undertakings, and PPH/ISA-eligible applicants.

On examination, a First Examination Report (FER) raises objections on novelty, inventive step, Section 3/4 bars, clarity, and disclosure. The applicant must respond and place the application in order within 6 months (extendable by 3 months), failing which the application is deemed abandoned. Persistent objections lead to a hearing before the Controller.

Opposition :

Pre-grant opposition (Section 25(1)):

Any person may file a representation (Form 7A) after publication, before grant. The Controller now screens for a prima facie case before admitting it (2024 amendment); the applicant’s reply period was shortened from 3 to 2 months.

Post-grant opposition (Section 25(2)):

Any “person interested” may oppose (Form 7) within 12 months of publication of grant. An Opposition Board reviews and recommends within 2 months (reduced from 3).

Revocation is also possible via the High Court, as a counterclaim in infringement suits, or by the Central Government under Section 66 (the IPAB having been abolished in 2021, with jurisdiction now vesting in High Courts).

Grant and Renewal :

Upon satisfaction of all requirements, the patent is granted and sealed (Section 43), valid for 20 years from filing (or international filing date for PCT applications). The 2024 amendment introduced Form 8A, letting inventors obtain a separate Certificate of Inventorship, since the patent certificate itself names only the patentee.

Renewal fees are payable annually from the 3rd year onward (nothing due for years 1–2), ranging roughly from ₹800/year (years 3–6) to ₹8,000/year (years 16–20) for the concessional category, five times higher for large entities. A 10% discount applies for advance e-filed payment of 4+ years. Lapsed patents can be restored within 18 months under Section 60.

Important Judgments :

• Bishwanath Prasad Radhey Shyam v. Hindustan Metal Industries (1979) — established the “person skilled in the art” test for obviousness.
• Novartis AG v. Union of India (2013) 6 SCC 1 — the Supreme Court held that Section 3(d) requires enhanced therapeutic efficacy, not mere improved physicochemical properties, rejecting Novartis’s Gleevec patent and cementing India’s anti-evergreening stance.
• Ferid Allani v. Union of India (Del HC, 2019) — clarified that computer-related inventions showing genuine “technical effect” are not barred by Section 3(k) merely for involving software.
• Monsanto Technology LLC v. Nuziveedu Seeds (2019) 3 SCC 381 — held that complex Section 3(j) validity questions on Bt cotton gene patents cannot be summarily decided.
• F. Hoffmann-La Roche v. Cipla (Del HC, 2015) — guided interim injunction standards in pharmaceutical patent litigation.
• Natco Pharma v. Bayer — India’s first compulsory license (2012), granted under Section 84 for Bayer’s Nexavar, on grounds of unaffordable pricing and inadequate local working.

Conclusion :

The 2024 amendments have materially sped up Indian patent prosecution — shorter RFE and opposition timelines, streamlined Form 27 working statements, and renewal incentives — while the substantive patentability bar, especially under Section 3(d), remains deliberately high to balance innovation incentives against public health access. Applicants should verify current fees and forms on ipindia.gov.in and engage a registered patent agent for significant filings.

References :

1. Sec 2(i)(j) Patents Act 1970
2. Section 3(d) Patents Act 1970
3. Section 3(k) Patents Act 1970
4. Section 9 Patents Act 1970
5. Section 10 Patents Act 1970
6. Section 25(1) Patents Act 1970
7. Section 25 (2) Patents Act 1970
8. Section 43 Patents Act 1970
9. Bishwanath Prasad Radhey Shyam v. Hindustan Metal Industries (1979)
10. Novartis AG v. Union of India (2013) 6 SCC 1
11. Ferid Allani v. Union of India (Del HC, 2019)
12. Monsanto Technology LLC v. Nuziveedu Seeds (2019) 3 SCC 381
13. F. Hoffmann-La Roche v. Cipla (Del HC, 2015)
14. Natco Pharma v. Bayer